EUVIMEDEUVIMED entdecken
Open Access

A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer

Heying Duan, Pejman Ghanouni, Bruce Daniel, Jarrett Rosenberg, Alan Thong, Christian Kunder, Carina Mari Aparici, Guido A Davidzon, Farshad Moradi, Geoffrey A Sonn, Andrei Iagaru

Journal of Nuclear Medicine · 2023-05 · 64 (5) · 744-750

DOI: 10.2967/jnumed.122.264448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.11.2022. Verfasst von Heying Duan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting of lesions seen on multiparametric MRI (mpMRI) improves prostate cancer (PC) detection at biopsy. However, 20%-65% of highly suspicious lesions on mpMRI (PI-RADS [Prostate Imaging-Reporting and Data System] 4 or 5) are false-positives (FPs), while 5%-10% of clinically significant PC (csPC) are missed. Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors (GRPRs) are both overexpressed in PC. We therefore aimed to evaluate the potential of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for biopsy guidance in patients with suspected PC.

Methods

A highly selective cohort of 13 men, aged 58.0 ± 7.1 y, with suspected PC (persistently high prostate-specific antigen [PSA] and PSA density) but negative or equivocal mpMRI results or negative biopsy were prospectively enrolled to undergo 68Ga-PSMA11 and 68Ga-RM2 PET/MRI. PET/MRI included whole-body and dedicated pelvic imaging after a delay of 20 min. All patients had targeted biopsy of any lesions seen on PET followed by standard 12-core biopsy. The SUVmax of suspected PC lesions was collected and compared with gold standard biopsy.

Results

PSA and PSA density at enrollment were 9.8 ± 6.0 (range, 1.5-25.5) ng/mL and 0.20 ± 0.18 (range, 0.06-0.68) ng/mL2, respectively. Standardized systematic biopsy revealed a total of 14 PCs in 8 participants: 7 were csPC and 7 were nonclinically significant PC (ncsPC). 68Ga-PSMA11 identified 25 lesions, of which 11 (44%) were true-positive (TP) (5 csPC). 68Ga-RM2 showed 27 lesions, of which 14 (52%) were TP, identifying all 7 csPC and also 7 ncsPC. There were 17 concordant lesions in 11 patients versus 14 discordant lesions in 7 patients between 68Ga-PSMA11 and 68Ga-RM2 PET. Incongruent lesions had the highest rate of FP (12 FP vs. 2 TP). SUVmax was significantly higher for TP than FP lesions in delayed pelvic imaging for 68Ga-PSMA11 (6.49 ± 4.14 vs. 4.05 ± 1.55, P = 0.023) but not for whole-body images, nor for 68Ga-RM2.

Conclusion

Our results show that 68Ga-PSMA11 and 68Ga-RM2 PET/MRI are feasible for biopsy guidance in suspected PC. Both radiopharmaceuticals detected additional clinically significant cancers not seen on mpMRI in this selective cohort. 68Ga-RM2 PET/MRI identified all csPC confirmed at biopsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingProstatic NeoplasmsMaleHumansGallium RadioisotopesProstate-Specific AntigenPilot ProjectsPositron-Emission TomographyBiopsyPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

68Ga-PSMA1168Ga-RM2PET/MRIbiopsy guidanceprostate cancer

Substanzen

Gallium RadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California.
  • Division of Body MRI, Department of Radiology, Stanford University, Stanford, California.
  • Department of Urology, Stanford University, Stanford, California; and.
  • Department of Pathology, Stanford University, Stanford, California.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; aiagaru@stanford.edu.

Zitieren

APA

Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., Aparici, C. M., Davidzon, G. A., Moradi, F., Sonn, G. A., & Iagaru, A. (2023). A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine, 64(5), 744-750. https://doi.org/10.2967/jnumed.122.264448

Vancouver

Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Kunder C, et al. A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine. 2023;64(5):744-750. doi:10.2967/jnumed.122.264448

BibTeX
@article{Duan2023,
  author = {Duan, Heying and Ghanouni, Pejman and Daniel, Bruce and Rosenberg, Jarrett and Thong, Alan and Kunder, Christian and Aparici, Carina Mari and Davidzon, Guido A and Moradi, Farshad and Sonn, Geoffrey A and Iagaru, Andrei},
  title = {A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {5},
  pages = {744--750},
  doi = {10.2967/jnumed.122.264448}
}
Kostenlos starten →